Treatment of steroid resistant nephrotic syndrome in children.

Achieving remission in children with steroid-resistant nephrotic syndrome (SRNS) could be difficult. Many immunosuppressive drugs are used with variable success rates. We have studied the response of children with SRNS who presented to our pediatric's renal unit between 2002 and 2007 to various modalities of therapy. We included patients with no response to prednisolone (60 mg/M2/day) after four weeks of therapy; all the patients had renal biopsy and followup duration for at least one year. We excluded patients with congenital nephrotic syndrome, lupus, or sickle cell disease. There were 31 (23 girls and 8 boys with F:M = 2.9:1; the mean age at presentation was 4.2 +/- 3.2) children who fulfilled the inclusion criteria. The mean duration of follow up was 3.1 +/- 1.6 years. Twenty children (65%) achieved partial (6 children) or complete (14 children) remission. There were 16 children treated with cyclophosphamide either oral or intravenous, and only 4 of them (25%) achieved remission. Seven children received oral chlorambucil, and only2 of them (28.5%) achieved remission; none of the children experienced side effects. Fifteen children received cyclosporine, and only eight of them (53%) achieved remission. Six children developed gum hypertrophy and one had renal impairment, which was reversible after discontinuing the drug. Mycophonelate mofetil (MMF) was used as the last option in 5 children, and 2 of them achieved complete remission. One child developed a systemic cytomegalovirus (CMV) infection which indicated discontinuing the drug. Fourteen (45%) children needed more than one immunosuppressive therapy. Three children progressed to end stage renal failure and required dialysis. We conclude that SRNS in children is a difficult disease with significant morbidity. However, remission is achievable with cyclosporine and other immunosuppressive agents. Treatment should be individualized according to the underlying histopathology, and clinical and social conditions of the children.

[1]  J. Tobin,et al.  Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis , 1996, Pediatric Nephrology.

[2]  H. Liapis.  Molecular Pathology of Nephrotic Syndrome in Childhood: A Contemporary Approach to Diagnosis , 2008, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[3]  J. Craig,et al.  Therapies for steroid-resistant nephrotic syndrome , 2008, Pediatric Nephrology.

[4]  J. Ehrich,et al.  Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  Marcos Paulo Hippólito da Silva,et al.  Is focal segmental glomerulosclerosis increasing in patients with nephrotic syndrome? , 2007, Pediatric Nephrology.

[6]  R. Hogg,et al.  Focal segmental glomerulosclerosis – epidemiology aspects in children and adults , 2007, Pediatric Nephrology.

[7]  N. Sebire,et al.  Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis , 2007, Pediatric Nephrology.

[8]  D. Gipson,et al.  Therapeutic approach to FSGS in children , 2007, Pediatric Nephrology.

[9]  J. Kari,et al.  Chlorambucil therapy in children with steroid-resistant nephrotic syndrome. , 2006, Saudi Medical Journal.

[10]  P. Niaudet.  Genetic forms of nephrotic syndrome , 2004, Pediatric Nephrology.

[11]  E. Lewis,et al.  Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. , 2004, Journal of the American Society of Nephrology : JASN.

[12]  A. Bakkaloğlu,et al.  Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. , 2004, Journal of the American Society of Nephrology : JASN.

[13]  J. Craig,et al.  Interventions for idiopathic steroid-resistant nephrotic syndrome in children. , 2004, The Cochrane database of systematic reviews.

[14]  J. Kari,et al.  Intravenous pulse cyclophosphamide—is it effective in children with steroid-resistant nephrotic syndrome? , 2003, Pediatric Nephrology.

[15]  J. Craig,et al.  Interventions for steroid-resistant nephrotic syndrome: a systematic review , 2003, Pediatric Nephrology.

[16]  M. Pollak.  The genetic basis of FSGS and steroid-resistant nephrosis. , 2003, Seminars in nephrology.

[17]  J. Kari.  Changing trends of histopathology in childhood nephrotic syndrome in western Saudi Arabia. , 2002, Saudi medical journal.

[18]  J. Tobin,et al.  Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. , 1997, Journal of the American Society of Nephrology : JASN.